India, March 24 -- CG Oncology, Inc. (CGON), Monday announced positive data from Phase 3 study of cretostimogene monotherapy for high-risk BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ.
The biopharmaceutical company noted that 75.5 percent of the participants achieved a complete response at any time, with 46 percent of subjects maintaining response at 12 months and 30 confirmed responses at 24 months.
The median duration of response has not been reached but exceeds 28 months, the company added. Moreover, there were no Grade 3 or greater treatment-related adverse events or deaths reported.
Currently, CG Oncology's stock is trading at $28.14, up 4.33 percent on the Nasdaq.
For comments and feedback contact: ed...